Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of venglustat versus standard treatment in Fabry disease with left ventricular hypertrophy
CTR20220800Phase 3Active
- Sponsor
- Sanofi
- Start
- Aug 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of venglustat in Fabry disease (FD) (2 arms), sponsored by Sanofi. Primary endpoint: Change in slope of left ventricular mass index from baseline to 18 months. Started Aug 2022; status: active.
02
Drugs
venglustat
03
Conditions
Fabry disease (FD)
Beyond the preview
Go deeper on CTR20220800.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20220800.